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No evidence  
suggests that  
hypercoagulopathy 
testing benefits 
most patients with 
DVT or predicts 
recurrence better 
than clinical risk 
assessment.
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EvidEncE-basEd answEr
A
	 Does	hypercoagulopathy		
testing	benefit	patients	with	DVT?	
	 no.	There	 is	no	evidence	 to	suggest	
	 that	 testing	 for	 hypercoagulopathy	
benefits	 most	 patients	 with	 deep	 venous	
thrombosis	 (DVT).	 Nor	 has	 research	 es-
tablished	 that	 thrombophilia	 test	 results	
improve	 the	 ability	 to	 predict	 recurrence	
better	 than	 clinical	 risk	 assessment	 alone	
(strength	 of	 recommendation	 [SOR]:	 B,	
multiple	cohort	studies).	
Testing	may	be	warranted	 in	patients	
younger	 than	 50	 years	 with	 idiopathic	
DVT	 or	 patients	 with	 recurrent	 episodes	
of	 thromboembolism	 to	 assess	 risk	 in	
other	 family	 members	 (SOR:	 C,	 expert	
opinion).	
A	 theoretical	 cost-benefit	 analysis	
demonstrates	that	testing	for	antiphospho-
lipid	 antibody	 syndrome	and	homozygous	
factor	V	Leiden	may	be	cost	effective	when	
comparing	quality-adjusted	life	years	in	pa-
tients	with	 idiopathic	DVT	 (SOR:	B,	 single	
cost-benefit	analysis).	
Evidence summary
For	 thrombophilia	 testing	 to	 be	 of	 clinical	
value	 in	patients	with	DVT,	 it	must	be	 supe-
rior	 to	 clinical	 history	 alone	 in	 determining	
who	is	at	risk	for	recurrence;	changing	therapy	
based	on	a	positive	test	must	improve	clinical	
outcomes.	
Testing doesn’t predict risk  
more accurately than clinical history
Several	thombophilic	conditions	are	associated	
with	 increased	risk	 for	both	first	and	recurrent	
DVT	 (TABLE).1-3	 Certain	 clinical	 characteristics	
also	markedly	 increase	 the	 risk	 of	 recurrence,	
including	breast	cancer	(when	the	patient	is	on	
chemotherapy),	lung,	pancreatic	and	other	gas-
trointestinal	cancers,	some	major	surgeries,	and	
a	history	of	previous	DVT.1,4	Three	cohort	studies	
show	 that	 thrombophilia	 test	 results	 don’t	 as-	
sess	recurrence	risk	more	accurately	than	these	
historical	factors	alone	for	most	patients.5-7	
Testing may be cost effective  
for patients with idiopathic DVT
Auerbach	and	colleagues	developed	a	math-
ematical	model	of	cost	effectiveness	and	con-
cluded	that	thrombophilia	testing	may	be	cost	
effective	 for	 patients	 with	 idiopathic	 DVT.8	
Their	 analysis	 was	 based	 on	 theoretical	 as-
sumptions	 that	might	 oversimplify	 the	 com-
plexities	of	practice,	however.	No	clinical	trials	
compare	different	 treatment	 regimens	based	
on	the	results	of	thrombophilia	tests.	
Prolonged anticoagulation 
may benefit high-risk patients
Few	studies	have	compared	various	durations	
of	 warfarin	 treatment	 for	 patients	 with	DVT.	
The	 risk	 of	 recurrence	 is	 highest	 in	 the	 first	
6	to	12	months	after	an	initial	episode.4	After	
12	months	the	risk	decreases,	but	never	to	the	
risk	level	of	people	who	have	never	had	a	DVT.	
A	Cochrane	meta-analysis	of	8	RCTs,	 to-
taling	 2994	 patients,	 evaluated	 duration	 of	
treatment	with	vitamin	K	antagonists	in	DVT.	
It	 concluded	 that	 although	 prolonged	 treat-
ment	with	vitamin	K	antagonists	reduces	the	
risk	of	DVT,	substantial	ongoing	risk	of	bleed-
ing	 complications	 remains.9	 Prolonged	 or	
even	lifelong	treatment	may	be	considered	for	
high-risk	 patients	 with	 multiple	 episodes	 of	
DVT	or	pulmonary	embolism.	
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Cost-effectiveness	 analysis	 suggests	 that	
prolonged	 warfarin	 therapy	 for	 patients	 with	
the	highest	risk	thrombophilic	conditions	(ho-
mozygous	factor	V	Leiden	and	antiphospholip-
id	antibody	syndrome)	also	may	be	warranted.8	
Recommendations
A	consensus	opinion	from	the	British	Society	
for	Haematology	concludes	that:
•		thrombophilia	testing	of	unselected	pa-
tients	is	inappropriate
•		initial	management	 of	 DVT	 or	 pulmo-
nary	 embolism	 in	 patients	 with	 heri-
table	thrombophilia	is	no	different	from	
that	in	other	patients
•		identification	of	the	most	prevalent	forms	
of	heritable	 thrombophilia,	heterozygous	
factor	V	Leiden	or	prothrombin	G20210A,	
shouldn’t	influence	decisions	about	dura-
tion	of	anticoagulation	therapy.10	
The	consensus	statement	suggests	indefi-
nite	anticoagulation	for	patients	with	2	or	more	
spontaneous	venous	thrombotic	events.								JFP
TABLE
Thrombophilic	conditions	that	increase	the	risk	of	DVT
Thrombophilic condition
Prevalence in patients 
with first dVT1 
relative risk of dVT  
compared with noncarriers1-3
Antithrombin deficiency 1% 5
Protein c 3% 3.1-3.4
Protein S 1%-2% 2
Factor V leiden 20% 1.14-2.12 (heterozygous) 
1.2-6.0 (homozygous)
Prothrombin G20210A 6% 1.9-2.8
Elevated anticardio-
lipin antibodies
14% 1.6-3.2
lupus anticoagulant 5%-15% 9-11
hyperhomocystinemia 10%-25% 2.7
dVT, deep vein thrombosis.
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